Abstract 2878: CRISPR-Cas9 screens identify the nuclear export factor NXT1 as a novel therapeutic target in MYCN-amplified neuroblastoma

MLA

David E. Root, et al. “Abstract 2878: CRISPR-Cas9 Screens Identify the Nuclear Export Factor NXT1 as a Novel Therapeutic Target in MYCN-Amplified Neuroblastoma.” Cancer Research, vol. 79, July 2019, p. 2878. EBSCOhost, https://doi.org/10.1158/1538-7445.am2019-2878.

APA

David E. Root, Michael V. Rothberg, Scott T. Younger, Alfredo Gonzalez, Francisca Vazquez, Brenton R. Paolella, Neekesh V. Dharia, Mai Abdusamad, Guillaume Kugener, Nancy Dumont, Clare F. Malone, & Kimberly Stegmaier. (2019). Abstract 2878: CRISPR-Cas9 screens identify the nuclear export factor NXT1 as a novel therapeutic target in MYCN-amplified neuroblastoma. Cancer Research, 79, 2878. https://doi.org/10.1158/1538-7445.am2019-2878

Chicago

David E. Root, Michael V. Rothberg, Scott T. Younger, Alfredo Gonzalez, Francisca Vazquez, Brenton R. Paolella, Neekesh V. Dharia, et al. 2019. “Abstract 2878: CRISPR-Cas9 Screens Identify the Nuclear Export Factor NXT1 as a Novel Therapeutic Target in MYCN-Amplified Neuroblastoma.” Cancer Research 79 (July): 2878. doi:10.1158/1538-7445.am2019-2878.